Stability of Essential Drugs in Tropical Climates: Zimbabwe - EDM Research Series No. 013
(1994; 86 pages) Voir le document au format PDF
Table des matières
Afficher le documentAbbreviations
Afficher le document1. Summary
Ouvrir ce répertoire et afficher son contenu2. Introduction
Ouvrir ce répertoire et afficher son contenu3. Study design and methods
Afficher le document4. Results
Ouvrir ce répertoire et afficher son contenu5. Discussion
Ouvrir ce répertoire et afficher son contenu6. Conclusions and recommendations
Afficher le documentReferences
Fermer ce répertoireAnnexes
Fermer ce répertoireAnnex 1: Detailed results for each drug
Afficher le document1.1 Amoxycillin capsules
Afficher le document1.2 Ampicillin capsules
Afficher le document1.3 Acetylsalicylic acid tablets
Afficher le document1.4 Doxycycline capsules
Afficher le document1.5 Ferrous sulfate tablets
Afficher le document1.6 Phenoxymethylpenicillin tablets
Afficher le document1.7 Tetracycline capsules
Afficher le document1.8 Retinol tablets
Afficher le document1.9 Epinephrine injection
Afficher le document1.10 Ampicillin injection
Afficher le document1.11 Benzylpenicillin injection
Afficher le document1.12 Ergometrine injection
Afficher le document1.13 Procaine penicillin injection
Afficher le documentAnnex 2: Validation of laboratory results
 

1.12 Ergometrine injection

SHELF LIFE

Manufacturers A, B, C: 2 years

ASSAY METHOD

HPLC method, USP 1990. Three ampoules mixed; measured three times; mean taken.

ASSAY LIMITS

90 - 110% (USP)

SAMPLES OBTAINED

All Manuf.

Manuf. A

Manuf. B

Manuf. C

                 

GMS samples

no.

%

no.

%

no.

%

no.

%

Total

26

100

21

81

4

15

1

4

Harare

13

50

           

Bulawayo

13

50

           

Facility samples

               

Total

67

100

31

46

9

13

27

40

Age > 50% SLife

40

60

           

Facility type = PCH

46

69

           

Climate = hot

48

72

           

Transport - slow

40

60

           

Unfrig. storage

8

12

           

Longitudinal series

               

Total

50

100

28

56

9

18

13

26

SUMMARY ESSAY RESULTS

 

All Manuf.

Manuf. A

Manuf. B

Manuf. C

GMS samples

no.

%

           

Mean age (mths)

 

3

 

1.7

 

6.9

 

14.5

Mean assay

 

82.4%

 

85.2%

 

65.1%

 

93.9%

95% CL

77.7 -87.1%

80.8 - 89.5%

57.1 - 73.0%

 

(93.9%)

No, and % fail

17

65%

13

62%

4

100%

0

0%

No. and % low fail

17

65%

13

62%

4

100%

0

0%

No. and % high fail

0

0%

0

0%

0

0%

0

0%

Facility samples

All Manuf.

Manuf. A

Manuf. B

Manuf. C

Mean age (mths)

 

13.5

 

8.6

 

17

 

17.8

Mean assay

 

73.6%

 

66.3%

 

57.9%

 

87.2%

95% CL

69.2 - 78.0%

60.0 - 72.0%

51.5 - 64.4%

81.8 - 92.6%

No, and % fail

48

72%

29

94%

9

100%

10

37%

No. and % low fail

48

72%

29

94%

9

100%

10

37%

No. and % high fail

0

0%

0

0%

0

0%

0

0%

Longitudinal series

at Manuf.

at GMS

at facility

   

Mean age (mths)

 

0

 

7.6

 

12.5

   

Mean assay

 

104.1%

 

83.8%

 

68.9%

   

95% CL

103.4 - 104.8%

80.4 - 87.1%

64.6- 73.2%

   

No. and % fail

0

0%

28

53%

46

87%

   
 

Mean interval (mths)

4.8

 

Mean loss (-) or gain (+)

-17.1%

 

95% CL for loss/gain

-21 7 to -12.6%


Figure 1 - Results of GMS samples


Figure 2 - Results of facility samples


Figure 3 - Difference between GMS/facility pairs


Figure 4 - GMS and facility results: Manufacturer A


Figure 5 - GMS and facility results: Manufacturer B


Figure 6 - GMS and facility results: Manufacturer C

Findings:

a) 12 of 79 facility samples (15%) were expired; these results were excluded.

b) 17 of 26 GMS samples (65%) failed; all failures were below the lower limit (minimum value 58.4%).

c) 48 of 67 facility samples (72%) failed; all failures were below the lower limit (minimum value 20.5%), However, a high value was obtained at 19.8 months for one Sample (Manufacturer C).

d) 50 GMS/facility sample pairs showed a mean loss of potency of -17.1% over a mean interval of 4.8 months.

e) There was a constant initial quality problem for two out of three manufacturers as indicated by the high failure rates (62% for Manufacturer A and 100% for Manufacturer B).

f) The facility samples of these two manufacturers' samples showed a decreased potency reflected by lower mean assays and higher fail rates (Manufacturer A's failures increased to 94% and Manufacturer B's had 100% failures as before).

g) The single GMS sample for Manufacturer C passed (93.9%) even though the age at sampling was 14.5 months.

h) Manufacturer C's facility samples showed a higher potency than those of Manufacturers A and B. However, 37% failed and the mean assay (87.2%) reflected some loss of potency at facility level.

i) The potency loss in GMS/facility pairs was significant (t-test, one tail, p<0.0005). This was the case for each of the manufacturers individually.

j) The conclusion is that all three manufacturers' products were unstable.

k) Manufacturers A and B showed an initial quality problem which worsened at facility level.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013